BR112022007676A2 - Composições e métodos para aumentar glutationa para uso na saúde cerebral - Google Patents

Composições e métodos para aumentar glutationa para uso na saúde cerebral

Info

Publication number
BR112022007676A2
BR112022007676A2 BR112022007676A BR112022007676A BR112022007676A2 BR 112022007676 A2 BR112022007676 A2 BR 112022007676A2 BR 112022007676 A BR112022007676 A BR 112022007676A BR 112022007676 A BR112022007676 A BR 112022007676A BR 112022007676 A2 BR112022007676 A2 BR 112022007676A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
brain health
glutathione
increase
Prior art date
Application number
BR112022007676A
Other languages
English (en)
Inventor
Sandi Carmen
Strasser Alina
Steiner Pascal
Preitner Nicolas
Trovo Laura
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa filed Critical Nestle Sa
Publication of BR112022007676A2 publication Critical patent/BR112022007676A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

COMPOSIÇÕES E MÉTODOS PARA AUMENTAR GLUTATIONA PARA USO NA SAÚDE CEREBRAL. A presente invenção se refere a composições e métodos para potencializar o aumento de glutationa para uso na saúde cerebral. Em particular, as composições e métodos da invenção são benéficos para uso em indivíduos que precisam aumentar o desempenho motivacional e/ou a energia mental, funções que podem ser diminuídas mediante estresse e ansiedade.
BR112022007676A 2019-11-18 2020-11-16 Composições e métodos para aumentar glutationa para uso na saúde cerebral BR112022007676A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19209825 2019-11-18
PCT/EP2020/082191 WO2021099241A1 (en) 2019-11-18 2020-11-16 Compositions and methods for glutathione enhancement for use in brain health

Publications (1)

Publication Number Publication Date
BR112022007676A2 true BR112022007676A2 (pt) 2022-08-09

Family

ID=68610053

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022007676A BR112022007676A2 (pt) 2019-11-18 2020-11-16 Composições e métodos para aumentar glutationa para uso na saúde cerebral

Country Status (8)

Country Link
US (1) US20230000806A1 (pt)
EP (1) EP4061387A1 (pt)
JP (1) JP2023502966A (pt)
CN (1) CN114786689A (pt)
AU (1) AU2020388433A1 (pt)
BR (1) BR112022007676A2 (pt)
CA (1) CA3158912A1 (pt)
WO (1) WO2021099241A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023131078A1 (en) * 2022-01-06 2023-07-13 Nanjing Nutrabuilding Bio-Tech Co., Ltd. Use of ergothioneine for enhancing glutathione level
WO2024052553A1 (en) * 2022-09-08 2024-03-14 Iasomai Ab Combination comprising n-acetyl-l-cysteine, selenomethionine and melatonine for treatment of anxiety disorder

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US5681578A (en) * 1996-01-22 1997-10-28 Sahley; Billie J. Composition for relieving stress anxiety, grief, and depression
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
WO2005120487A2 (de) * 2004-06-11 2005-12-22 Egon Tech Präparat zur prophylaxe und therapie von stresszuständen, von funktionellen und organischen störungen des nervensystems und des stoffwechsels
US20060257502A1 (en) * 2005-05-11 2006-11-16 Jiankang Liu A combination of mitochondrial nutrients for relieving stress, preventing and improving stress-related disorders
CN1985993B (zh) * 2006-12-29 2012-04-04 安徽辉克药业有限公司 增强记忆力的复方制剂
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
WO2008100727A2 (en) * 2007-02-14 2008-08-21 The Trustees Of Columbia University In The City Of New York High-dose glycine as a treatment for obsessive-compulsive disorder and obsessive-compulsive spectrum disorders
US20120128711A1 (en) * 2009-09-21 2012-05-24 Total Nutraceutical Solutions, Inc. Anti-inflammatory approach to prevention and suppression of post-traumatic stress disorder, traumatic brain injury, depression and associated disease states
KR101401744B1 (ko) * 2010-09-06 2014-06-02 서울대학교산학협력단 Ｎ-아세틸-ｌ-시스테인 또는 이의 유도체를 포함하는 불안 장애 치료용 약학 조성물
US20120141611A1 (en) * 2010-12-05 2012-06-07 Oxis International Inc. Methods and compositions using ergothioneine to treat a variety of health related factors
US20140107140A1 (en) * 2011-06-24 2014-04-17 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of gulf war illness
WO2013188877A1 (en) * 2012-06-15 2013-12-19 Promentis Pharmaceuticals, Inc. The use of compounds elevating glutathione levels for the treatment of parkinson's disease
US9101580B2 (en) * 2012-12-18 2015-08-11 Matthew Bennett Compositions and methods for treating traumatic brain injury
RU2519755C1 (ru) * 2013-01-25 2014-06-20 Николай Борисович Леонидов Анксиолитик и способ его получения
US20140348795A1 (en) * 2013-05-24 2014-11-27 Helmut Wyzisk Nutritional beverage powder and method of making same
US20150132273A1 (en) * 2013-11-09 2015-05-14 Rhett Sean Daniels Nutritional Compositions and Methods for Treating Cognitive Impairment
AU2016268340B2 (en) * 2015-05-28 2021-07-08 Baylor College Of Medicine Benefits of supplementation with N-acetylcysteine and glycine to improve glutathione levels
CA2989743A1 (en) * 2015-06-19 2016-12-22 Harsha CHIGURUPATI Synergistic beverage composition
EP3618824A4 (en) * 2017-05-02 2021-06-23 Neuronasal, LLC USE OF N-ACETYLCYSTONE FOR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

Also Published As

Publication number Publication date
CA3158912A1 (en) 2021-05-27
JP2023502966A (ja) 2023-01-26
US20230000806A1 (en) 2023-01-05
WO2021099241A1 (en) 2021-05-27
AU2020388433A1 (en) 2022-04-14
CN114786689A (zh) 2022-07-22
EP4061387A1 (en) 2022-09-28

Similar Documents

Publication Publication Date Title
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
CL2017002184A1 (es) Composición que comprende sialillactosa para usar en la mejora de las aptitudes de aprendizaje y la función de memoria.
BR112015006402A2 (pt) conjunto de pelo menos uma proteína vegetal e pelo menos uma proteína láctea
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
CR20150199A (es) Análogos de 2´-cloro nucleósido para infección por vhc
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
BR112015027327A2 (pt) composições e métodos para alterar a sinalização do mensageiro secundário
BR112013000537A2 (pt) composição aquosa contendo bromexina
GT201400033A (es) Pirimidinas anilladas sustituidas y uso de las mismas
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CU20140082A7 (es) Pirimidinas y triazinas fusionadas sustituidas y sus uso
BR112014030903A2 (pt) máquina de bebida com inibidor de vibração
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
BR112022007676A2 (pt) Composições e métodos para aumentar glutationa para uso na saúde cerebral
BR112014030282A2 (pt) métodos de tratamento de excesso de peso e obesidade
CR20110100A (es) Nuevos derivados de sulfamida sustituida
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
BR112018076283A2 (pt) métodos e composições para potencializar terapias de célula tronco
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
ECSP16057765A (es) Composiciones y métodos para reducir eventos adversos cardiovasculares graves
BR112015024926A2 (pt) composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe
CO2017004735A2 (es) Moléculas que tienen utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
CL2020003074A1 (es) Inhibidores de la vía de respuesta al estrés integrada.
BR112016006388A2 (pt) inibidor seletivo da fosfatidilinositol 3-quinase gama
BR112013028568A2 (pt) roda de trilho e método para produzir uma roda de trilho